KR20180114440A - Skin-whitening cosmetic composition containing sodium riboflavin phosphate or phytantriol as a active ingredient - Google Patents
Skin-whitening cosmetic composition containing sodium riboflavin phosphate or phytantriol as a active ingredient Download PDFInfo
- Publication number
- KR20180114440A KR20180114440A KR1020170046205A KR20170046205A KR20180114440A KR 20180114440 A KR20180114440 A KR 20180114440A KR 1020170046205 A KR1020170046205 A KR 1020170046205A KR 20170046205 A KR20170046205 A KR 20170046205A KR 20180114440 A KR20180114440 A KR 20180114440A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- riboflavin phosphate
- present
- active ingredient
- phytantriol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 title claims abstract description 51
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 title claims abstract description 19
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 title claims abstract description 17
- 239000002537 cosmetic Substances 0.000 title claims description 26
- 230000002087 whitening effect Effects 0.000 claims abstract description 44
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 230000036541 health Effects 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 208000012641 Pigmentation disease Diseases 0.000 claims abstract description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 33
- 102000003425 Tyrosinase Human genes 0.000 claims description 20
- 108060008724 Tyrosinase Proteins 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 13
- 230000008099 melanin synthesis Effects 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000008234 soft water Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims 1
- 239000000516 sunscreening agent Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 34
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 22
- 201000001441 melanoma Diseases 0.000 description 18
- 238000009472 formulation Methods 0.000 description 13
- DQCINBZXWARKBZ-UHFFFAOYSA-N 2h-pyran-2,3,4-triol Chemical compound OC1OC=CC(O)=C1O DQCINBZXWARKBZ-UHFFFAOYSA-N 0.000 description 12
- 229960000271 arbutin Drugs 0.000 description 12
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- -1 fatty acid esters Chemical class 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000013641 positive control Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 229960001855 mannitol Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229940033134 talc Drugs 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229950001574 riboflavin phosphate Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- 235000012241 calcium silicate Nutrition 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 2
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019234 riboflavin-5-sodium phosphate Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate) 또는 피탄트리올(phytantriol)을 유효성분으로 포함하는 피부 미백용 조성물에 관한 것으로, 구체적으로 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물; 피부 미백 개선용 피부 외용제; 피부 미백 개선용 건강기능식품; 또는 피부 색소 침착의 예방 또는 치료용 약학적 조성물에 관한 것이다.The present invention relates to a skin whitening composition comprising sodium riboflavin phosphate or phytantriol as an active ingredient. More specifically, the present invention relates to a composition for skin whitening comprising one kind selected from the group consisting of sodium riboflavin phosphate and phytantriol A cosmetic composition for skin whitening comprising a compound or an acceptable salt thereof as an active ingredient; External skin preparations for improving skin whitening; Health functional foods for improving skin whitening; Or skin pigmentation. ≪ RTI ID = 0.0 > [0002] < / RTI >
사람의 피부색은 피부 내 멜라닌(melanin)의 농도와 분포에 따라 유전적으로 결정되나, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다.The skin color of a person is genetically determined by the concentration and distribution of melanin in the skin, but is also influenced by environmental or physiological conditions such as sunlight, fatigue, and stress.
피부의 색을 결정하는 멜라닌 생성에 대한 화학적 작용은 현재까지 여러 논문 등을 통해 많이 보고되고 있는데, 멜라닌 생성세포인 멜라노사이트 (melanocyte)가 멜라노좀(melanosome)이라는 세포 내 소기관에서 자외선으로부터 세포를 보호하는 기능을 가지는 멜라닌을 합성하고, 합성된 멜라닌은 멜라노사이트에서 각질형성세포(keratinocyte)로 이동하며, 이렇게 각질형성세포로 이동된 멜라닌이 피부색을 결정하는 것으로 알려져 있다.The chemical action of melanogenesis, which determines the color of skin, has been reported so far in various papers and the like. Melanocyte, a melanocyte, protects cells from ultraviolet rays in the intracellular organelle called melanosome And synthesized melanin is transferred from melanocyte to keratinocyte, and it is known that melanin transferred to keratinocyte cells determines skin color.
상기 멜라닌 생합성 과정에 필요한 전구물질은 티로신(tyrosine)이라는 아미노산으로, 이 티로신은 디히드록시페닐알라닌(dihydroxyphenylalanine, DOPA)으로 전환되고, 그 후 도파퀴논(dopaquinone)이라는 물질 등을 거쳐 최종적으로 멜라닌으로 전환된다고 알려져 있다. 이렇게 합성된 멜라닌은 피부색을 짙게 만드는데, 건강 또는 미용상의 요구로 인해 상기 멜라닌 합성을 억제하여 피부색을 밝게 하려는 피부 미백 방법에 관한 연구가 활발히 진행 중이다.The precursor required for the melanin biosynthesis process is an amino acid called tyrosine. This tyrosine is converted into dihydroxyphenylalanine (DOPA), and then converted to melanin through a substance called dopaquinone . The synthesized melanin makes the skin darker. Studies on skin whitening method to suppress skin melanin synthesis and brighten skin color due to health or cosmetic demand are actively under way.
일반적으로 알려진 미백 성분으로서, 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 타이로시네이즈(tyrosinase) 활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민 C(L-Ascorbic acid) 또는 이들의 유도체와 각종 식물 추출물이 있다. 이들은 멜라닌 색소의 합성을 저해함으로써, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다. 그러나 피부 적용 시, 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적인 효과를 기대할 수 없는 문제점이 있다.As a generally known whitening ingredient, there may be mentioned a substance inhibiting tyrosinase activity such as kojic acid or arbutin, hydroquinone, L-ascorbic acid, Derivatives and various plant extracts. By inhibiting the synthesis of melanin pigment, they can brighten the skin tone to realize skin whitening, and it is possible to improve skin hypercholesterolemia such as stain or freckles due to ultraviolet rays, hormones or heredity. However, when applied to skin, there is a problem that the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant, so that a practical effect can not be expected.
한편, 리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate)은 분자식 C17H20N4NaO9P, 분자량 478.33을 가지는 화합물로서, NADH 탈수소효소(NADH dehydrogenase)를 포함한 여러 산화 효소의 보조효소로서 작용한다. 치아 미백 용도로 사용될 수 있음이 알려져 있으나, 리보플라빈 포스페이트 나트륨이 직접적으로 피부 미백 효과를 가지는 것에 대해서는 밝혀진 바가 없었다.On the other hand, riboflavin phosphate is a compound having the molecular formula C 17 H 2 O 4 NaO 9 P and molecular weight of 478.33, and acts as a coenzyme of various oxidases including NADH dehydrogenase. It is known that it can be used for tooth whitening purposes, but it has not been known that sodium riboflavin phosphate directly has a skin whitening effect.
또한, 피탄트리올(phytantriol)은 분자식 C20H42O3, 분자량 330.553을 가지는 화합물로서, 손상된 모발을 보호하고 개선할 수 있음이 알려져 있으나, 피탄트리올이 직접적으로 피부 미백 효과를 가지는 것에 대해서는 밝혀진 바가 없었다.It is also known that phytantriol is a compound having the molecular formula C 20 H 42 O 3 and a molecular weight of 330.553. It is known that it is possible to protect and improve damaged hair. However, it is known that phytantriol has a direct skin whitening effect It was not revealed.
이러한 배경하에서, 본 발명자들은 피부 미백 효과가 우수한 물질에 관하여 연구를 수행하였으며, 리보플라빈 포스페이트 나트륨 또는 피탄트리올을 유효성분으로 포함하는 조성물이 멜라닌 합성 억제 및 멜라닌 총량 감소 효과를 나타냄을 규명함으로써, 이를 활용한 피부 미백용 화장료 조성물, 피부 외용제, 건강기능식품 및 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 완성하기에 이르렀다.Under these circumstances, the inventors of the present invention conducted studies on a substance having excellent skin whitening effect, and found that a composition containing riboflavin phosphate sodium or phytantriol as an active ingredient exhibits an effect of suppressing melanin synthesis and reducing the total amount of melanin, A cosmetic composition for skin whitening, an external preparation for skin, a health functional food, and a pharmaceutical composition for preventing or treating skin pigmentation have been completed.
본 발명의 하나의 목적은, 리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate) 및 피탄트리올(phytantriol)로 구성된 군에서 선택되는 1종의 화합물 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytantriol or a cosmetically acceptable salt thereof as an active ingredient .
구체적으로, 본 발명의 목적은 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공하는 것이다.Specifically, the object of the present invention is to provide a cosmetic composition for skin whitening comprising, as an active ingredient, one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytotriol or a cosmetically acceptable salt thereof.
또한 구체적으로, 본 발명의 목적은 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 미백 개선용 피부 외용제를 제공하는 것이다.More specifically, it is an object of the present invention to provide a skin external preparation for improving skin whitening comprising one kind of compound selected from the group consisting of sodium riboflavin and phytotriol or an acceptable salt thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백 개선용 건강기능식품을 제공하는 것이다.More specifically, the object of the present invention is to provide a health functional food for skin whitening improvement comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytotriol or a pharmaceutically acceptable salt thereof as an active ingredient will be.
또한 구체적으로, 본 발명의 목적은 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.More specifically, it is an object of the present invention to provide a pharmaceutical composition for prevention or treatment of skin pigmentation comprising, as an active ingredient, one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytanetriol or a pharmaceutically acceptable salt thereof To provide a composition.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This will be described in detail as follows. On the other hand, each description and embodiment disclosed in the present invention can be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present invention fall within the scope of the present invention. Further, the scope of the present invention is not limited by the detailed description described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는 리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate) 및 피탄트리올(phytantriol)로 구성된 군에서 선택되는 1종의 화합물 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공한다.One aspect of the present invention for achieving the above object is a pharmaceutical composition comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytantriol or a cosmetically acceptable salt thereof as an active ingredient ≪ / RTI >
[화학식 1][Chemical Formula 1]
본 발명에서 "리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate)"은 상기 화학식 1로 표시되고, 분자식 C17H20N4NaO9P, 분자량 478.33을 갖는다. NADH 탈수소효소(NADH dehydrogenase)를 포함한 여러 산화 효소의 보조효소로서 작용하며, 치아 미백 용도로 사용될 수 있음이 알려져 있으나, 리보플라빈 포스페이트 나트륨 자체의 피부 미백 효과에 대해서는 밝혀진 바가 없었다.In the present invention, "sodium riboflavin phosphate" has the molecular formula C 17 H 2 O N 4 NaO 9 P and molecular weight of 478.33 represented by the above formula (1). It is known that it acts as a coenzyme of various oxidases including NADH dehydrogenase and can be used for tooth whitening. However, the skin whitening effect of sodium riboflavin phosphate itself has not been disclosed.
이때, 리보플라빈 포스페이트 나트륨의 화장품학적으로 허용 가능한 염의 구체적인 예로서, 리보플라빈-5'-포스페이트 나트륨염 2수화물(Riboflavin-5'-phosphate sodium salt dehydrate), 리보플라빈 나트륨 포스페이트(Riboflavin sodium phosphate), 리보플라빈-5'-포스페이트 나트륨염 수화물(Riboflavin 5'-phosphate sodium salt hydrate) 또는 리보플라빈 5'-1인산염 나트륨염(Riboflavin 5'-monophosphate sodium salt)일 수 있으나, 이에 제한되는 것은 아니다.Herein, specific examples of the cosmetically acceptable salts of sodium riboflavin phosphate include Riboflavin-5'-phosphate sodium salt dehydrate, Riboflavin sodium phosphate, Riboflavin-5 sodium phosphate, Phosphate salt salt hydrate, or Riboflavin 5'-monophosphate sodium salt, but the present invention is not limited thereto.
[화학식 2](2)
본 발명에서 "피탄트리올(phytantriol)"은 상기 화학식 2로 표시되고, 분자식 C20H42O3, 분자량 330.553을 가지며, 3,7,11,15-테트라메틸헥사데칸-1,2,3-트리올(3,7,11,15-Tetramethylhexadecane-1,2,3-triol) 또는 1,2,3-트리히드록시-3,7,11,15-테트라메틸헥사데칸( 1,2,3-Trihydroxy-3,7,11,15-tetramethylhexadecane) 등으로도 명명된다. 손상된 모발을 보호하고 개선할 수 있음이 알려져 있으나, 피탄트리올 자체의 피부 미백 효과에 대해서는 밝혀진 바가 없었다.In the present invention, "phytantriol" is a compound represented by the above formula (2) and having molecular formula C 20 H 42 O 3 , a molecular weight of 330.553, and 3,7,11,15-tetramethylhexadecane- Triol (3,7,11,15-Tetramethylhexadecane-1,2,3-triol) or 1,2,3-trihydroxy-3,7,11,15-tetramethylhexadecane (1,2, 3-Trihydroxy-3,7,11,15-tetramethylhexadecane). It is known that damaged hair can be protected and improved, but the skin whitening effect of pyranetriol itself has not been disclosed.
상기 리보플라빈 포스페이트 나트륨 및/또는 피탄트리올의 획득 방법은 특별히 한정되지 않으며, 당업계에 공지된 방법을 이용하여 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다.The method for obtaining riboflavin phosphate sodium and / or pyrantriol is not particularly limited and may be chemically synthesized using a method known in the art, or a commercially available material may be used.
본 발명의 화학식 1로 표시되는 리보플라빈 포스페이트 나트륨 및/또는 화학식 2로 표시되는 피탄트리올은 용매화된 형태뿐만 아니라 비-용매화된(unsolvated) 형태로 존재할 수도 있다. 본 발명의 리보플라빈 포스페이트 나트륨 및/또는 피탄트리올은 결정형 또는 무정형 형태로 존재할 수 있으며, 이러한 모든 물리적 형태는 본 발명의 범위에 포함된다.The riboflavin phosphate sodium represented by the formula (1) of the present invention and / or the pyranthr olol represented by the formula (2) may exist not only in a solvated form but also in an unsolvated form. The riboflavin phosphate sodium and / or pyrantriol of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.
구체적으로, 본 발명에 따른 조성물에 있어, 상기 리보플라빈 포스페이트 나트륨 또는 피탄트리올의 함량은 조성물 전체 중량 대비 0.0001 내지 10 중량%일 수 있으며, 보다 구체적으로 조성물 전체 중량 대비 0.0001 내지 5 중량%일 수 있다. 보다 더 구체적으로, 상기 리보플라빈 포스페이트 나트륨 또는 피탄트리올의 함량은 조성물 전체 중량 대비 0.0001 내지 0.006 중량%일 수 있으며, 가장 구체적으로 0.002 내지 0.0004 중량%일 수 있으나, 이에 한정된 것은 아니다.Specifically, in the composition according to the present invention, the content of sodium riboflavin phosphate or phytanetriol may be 0.0001 to 10% by weight based on the total weight of the composition, more specifically 0.0001 to 5% by weight based on the total weight of the composition . More specifically, the content of sodium riboflavin phosphate or phytotriol may be 0.0001 to 0.006 wt%, and most specifically 0.002 to 0.0004 wt%, based on the total weight of the composition, but is not limited thereto.
본 발명은 리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate) 및 피탄트리올(phytantriol)로 구성된 군에서 선택되는 1종의 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytantriol, or a cosmetically acceptable salt thereof.
또한, 구체적으로, 본 발명은 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 피부 미백용 화장료 조성물을 제공할 수 있다.In particular, the present invention can provide a cosmetic composition for skin whitening comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytotriol, or a cosmetically acceptable salt thereof.
본 발명에 있어서, "리보플라빈 포스페이트 나트륨" 및 "피탄트리올"은 상기에서 설명한 바와 같다.In the present invention, "riboflavin phosphate sodium" and "pyrantriol" are as described above.
본 발명에 있어서, "화장품학적으로 허용 가능한 염"은 리보플라빈 포스페이트 나트륨 및/또는 피탄트리올이 다른 물질과 결합한 염의 형태인 것으로, 화장품학적으로 만니톨과 비슷한 활성을 나타낼 수 있는 물질을 의미한다.In the present invention, "a cosmetically acceptable salt" refers to a substance which is in the form of a salt in which riboflavin phosphate sodium and / or pyranetriol are combined with other substances and which can exhibit similar activity to mannitol as a cosmetically.
본 발명에 있어서, "피부 미백"이라 함은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 말한다.In the present invention, "skin whitening" refers to not only brightening the skin tone by inhibiting the synthesis of melanin pigment but also improving skin hypercholesterolemia due to ultraviolet rays, hormones or heredity, such as spots or freckles.
본 발명의 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)에 첨가한 후 멜라닌 총량을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 우수한 멜라닌 총량 감소 효과를 나타내어, 화학식 1 또는 2로 표시되는 화합물을 포함하는 조성물은 피부 미백용 화장료 조성물로 사용될 수 있음을 확인하였다(표 1).In one embodiment of the present invention, the compound of formula (1) or (2) was added to rat melanoma cell (B-16 mouse melanoma cell) and the total amount of melanin was measured. Melanin total amount, indicating that the composition containing the compound represented by Formula 1 or 2 can be used as a cosmetic composition for skin whitening (Table 1).
또한, 본 발명의 다른 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포에 첨가하여 세포 수준에서의 타이로시네이즈 활성 저해 효과를 확인한 결과, 상기 화합물은 농도 의존적으로 멜라노마 세포의 타이로시네이즈 활성 감소 효과를 나타내었으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 타이로시네이즈의 활성을 저해함을 확인하여, 상기 화학식 1 또는 2로 표시되는 화합물은 피부 미백용 화장료 조성물로 사용될 수 있음을 재확인하였다(표 2).In another embodiment of the present invention, the compound represented by the formula (1) or (2) was added to rat melanoma cells to examine the inhibitory effect on tyrosinase activity at the cell level. As a result, In particular, it was confirmed that tyrosinase activity was inhibited even at a lower concentration than that of arbutin used as a positive control, and thus the compound represented by the above formula (1) or (2) It can be used as a cosmetic composition for whitening (Table 2).
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention can be used as a cosmetic composition in the form of a solution, an ointment for external use, a cream, a foam, a nutritional lotion, a softening water, a pack, a soft water, an emulsion, a makeup base, But are not limited to, emulsions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays It is not.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a general skin cosmetic composition, and examples thereof include oil, water, a surfactant, a moisturizer, A thickening agent, a chelating agent, a coloring matter, an antiseptic, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, a paste, a cream or a gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Mixtures of these may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as the carrier component, Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil may be used, in particular fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycols or sorbitan may be used have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerol, .
본 발명의 다른 하나의 양태는 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 미백 개선용 피부 외용제를 제공한다.Another aspect of the present invention provides an external preparation for skin for improving skin whitening comprising, as an active ingredient, one kind of compound selected from the group consisting of sodium riboflavin phosphate and pyranetriol or an acceptable salt thereof.
본 발명에 있어서, "리보플라빈 포스페이트 나트륨" 및 "피탄트리올"은 상기에서 설명한 바와 같다.In the present invention, "riboflavin phosphate sodium" and "pyrantriol" are as described above.
본 발명에 있어서, "허용 가능한 염"이란, 리보플라빈 포스페이트 나트륨 및/또는 피탄트리올이 다른 물질과 결합한 염의 형태인 것으로, 리보플라빈 포스페이트 나트륨 및/또는 피탄트리올과 비슷한 활성을 나타낼 수 있는 물질을 의미한다.In the present invention, "acceptable salt" means a substance which is in the form of a salt in which sodium riboflavin and / or pyrantriol are combined with other substances and can exhibit an activity similar to riboflavin phosphate sodium and / or pyrantriol do.
본 발명의 용어 "피부 외용제"는 일반적으로 피부 외용에 사용하는 물질 전반을 포함하는 포괄하는 개념으로, 피부 외용제 제형의 비제한적인 예로는 경고제(PLASTERS), 로션제(LOTIONS), 리니멘트제(LINIMENTS), 액제(LIQUIDS AND SOLUTIONS), 에어로솔제(AEROSOLS), 엑스제(EXTRACTS), 연고제(OINTMENTS), 유동엑스제(FLUIDEXTRACTS), 유제(EMULSIONS), 현탁제(SUSPESIONS), 캅셀제(CAPSULES), 크림제(CREAMS), 연질, 경질 젤라틴 캅셀, 첩부제, 또는 서방화제제가 있다.The term "external preparation for skin" of the present invention is a generic concept including the entirety of materials used for external skin application. Non-limiting examples of external preparations for skin include PLASTERS, LOTIONS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS, SUSPENSIONS, CAPSULES, , Creams (CREAMS), soft, hard gelatin capsules, pastes, or sustained release preparations.
본 발명의 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)에 첨가한 후 멜라닌 총량을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 우수한 멜라닌 총량 감소 효과를 나타내어, 화학식 1 또는 2로 표시되는 화합물을 포함하는 조성물은 피부 미백용 화장료 조성물로 사용될 수 있음을 확인하였다(표 1).In one embodiment of the present invention, the compound of formula (1) or (2) was added to rat melanoma cell (B-16 mouse melanoma cell) and the total amount of melanin was measured. Melanin total amount, indicating that the composition containing the compound represented by Formula 1 or 2 can be used as a cosmetic composition for skin whitening (Table 1).
또한, 본 발명의 다른 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포에 첨가하여 세포 수준에서의 타이로시네이즈 활성 저해 효과를 확인한 결과, 상기 화합물은 농도 의존적으로 멜라노마 세포의 타이로시네이즈 활성 감소 효과를 나타내었으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 타이로시네이즈의 활성을 저해함을 확인하여, 상기 화학식 1 또는 2로 표시되는 화합물은 피부 미백용 화장료 조성물로 사용될 수 있음을 재확인하였다(표 2).In another embodiment of the present invention, the compound represented by the formula (1) or (2) was added to rat melanoma cells to examine the inhibitory effect on tyrosinase activity at the cell level. As a result, In particular, it was confirmed that tyrosinase activity was inhibited even at a lower concentration than that of arbutin used as a positive control, and thus the compound represented by the above formula (1) or (2) It can be used as a cosmetic composition for whitening (Table 2).
본 발명에 따른 피부 외용제는 상용되는 무기 또는 유기의 담체, 부형제 및 희석제를 가하여 고체, 반고체 또는 액상의 형태로 제제화된 비경구 투여제일 수 있다. 상기 비경구 투여를 위한 제재로는 점적제, 연고, 로션, 겔, 크림, 패취, 스프레이, 현탁제 및 유제로 이루어진 군에서 선택되는 경피 투여형 제형일 수 있으나, 이에 제한되지 않는다.The external preparation for skin according to the present invention may be a parenteral dosage form which is formulated in solid, semi-solid or liquid form by adding a compatible inorganic or organic carrier, excipient and diluent. The preparation for parenteral administration may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions, and emulsions.
상기 외용제에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. Examples of the carrier, excipient and diluent which can be contained in the external preparation include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
각 제형에 의한 피부 외용제 조성물에 있어서, 상기한 본 발명의 조성물 이외의 다른 성분들을 기타 피부 외용제의 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용할 경우 상승효과가 일어날 수 있다.In the composition for external application for skin according to each formulation, components other than the composition of the present invention may be mixed and selected without difficulty by those skilled in the art depending on the formulation or use purpose of other external preparation for skin, etc. In this case, A synergistic effect can occur.
본 발명의 또 다른 하나의 양태는 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 미백 개선용 건강기능식품을 제공한다.Another aspect of the present invention provides a health functional food for improving skin whitening comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytotriol or a pharmaceutically acceptable salt thereof as an active ingredient do.
본 발명에 있어서, "리보플라빈 포스페이트 나트륨" 및 "피탄트리올"은 상기에서 설명한 바와 같다.In the present invention, "riboflavin phosphate sodium" and "pyrantriol" are as described above.
본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 건강기능식품은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 미백 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present invention, the term "health functional food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. The term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The health functional food of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has advantages in that it does not have side effects that may occur when a food is used as a raw material for a long period of time, and has excellent portability. Can be ingested as an adjunct to improve the skin whitening effect.
본 발명의 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)에 첨가한 후 멜라닌 총량을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 우수한 멜라닌 총량 감소 효과를 나타내어, 화학식 1 또는 2로 표시되는 화합물을 포함하는 조성물은 피부 미백용 화장료 조성물로 사용될 수 있음을 확인하였다(표 1).In one embodiment of the present invention, the compound of formula (1) or (2) was added to rat melanoma cell (B-16 mouse melanoma cell) and the total amount of melanin was measured. Melanin total amount, indicating that the composition containing the compound represented by Formula 1 or 2 can be used as a cosmetic composition for skin whitening (Table 1).
또한, 본 발명의 다른 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포에 첨가하여 세포 수준에서의 타이로시네이즈 활성 저해 효과를 확인한 결과, 상기 화합물은 농도 의존적으로 멜라노마 세포의 타이로시네이즈 활성 감소 효과를 나타내었으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 타이로시네이즈의 활성을 저해함을 확인하여, 상기 화학식 1 또는 2로 표시되는 화합물은 피부 미백용 화장료 조성물로 사용될 수 있음을 재확인하였다(표 2).In another embodiment of the present invention, the compound represented by the formula (1) or (2) was added to rat melanoma cells to examine the inhibitory effect on tyrosinase activity at the cell level. As a result, In particular, it was confirmed that tyrosinase activity was inhibited even at a lower concentration than that of arbutin used as a positive control, and thus the compound represented by the above formula (1) or (2) It can be used as a cosmetic composition for whitening (Table 2).
본 발명의 건강기능식품은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
상기 외에 본 발명의 건강기능식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강식품 100 중량부 당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, A carbonating agent used in a carbonated beverage, and the like. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
본 발명의 또 다른 하나의 양태는 리보플라빈 포스페이트 나트륨 및 피탄트리올로 구성된 군에서 선택되는 1종의 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 제공한다.Another aspect of the present invention is a pharmaceutical composition for preventing or treating skin pigmentation comprising, as an active ingredient, one compound selected from the group consisting of sodium riboflavin phosphate and pyranthr olol, or a pharmaceutically acceptable salt thereof. Gt;
본 발명에 있어서, "리보플라빈 포스페이트 나트륨" 및 "피탄트리올"은 상기에서 설명한 바와 같다.In the present invention, "riboflavin phosphate sodium" and "pyrantriol" are as described above.
본 발명에 있어서, "약학적으로 허용 가능한 염"이란 리보플라빈 포스페이트 나트륨 및/또는 피탄트리올이 다른 물질과 결합한 염의 형태인 것으로, 약학적으로 만니톨과 비슷한 활성을 나타낼 수 있는 물질을 의미한다.In the present invention, "pharmaceutically acceptable salt" means a salt in which sodium riboflavin and / or pyrantriol are combined with other substances, and means a substance which can exhibit similar activity to mannitol pharmacologically.
본 발명에 있어서, "피부 색소 침착"은 피부, 손발톱, 구강이나 비강을 둘러싸고 있는 점막 등에 멜라닌 증가에 의해 발생한 과다 색소 침착 반(macule)을 의미하며, 과색소침착이라고도 한다.In the present invention, "skin pigmentation" refers to a hyperpigmentation macule caused by an increase of melanin in skin, nail, mucous membrane surrounding oral cavity or nasal cavity, and is also called hyperpigmentation.
본 발명의 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)에 첨가한 후 멜라닌 총량을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 우수한 멜라닌 총량 감소 효과를 나타내어, 화학식 1 또는 2로 표시되는 화합물을 포함하는 조성물은 피부 미백용 화장료 조성물로 사용될 수 있음을 확인하였다(표 1).In one embodiment of the present invention, the compound of formula (1) or (2) was added to rat melanoma cell (B-16 mouse melanoma cell) and the total amount of melanin was measured. Melanin total amount, indicating that the composition containing the compound represented by Formula 1 or 2 can be used as a cosmetic composition for skin whitening (Table 1).
또한, 본 발명의 다른 일 실시예에서는, 화학식 1 또는 2로 표시되는 화합물을 쥐의 멜라노마 세포에 첨가하여 세포 수준에서의 타이로시네이즈 활성 저해 효과를 확인한 결과, 상기 화합물은 농도 의존적으로 멜라노마 세포의 타이로시네이즈 활성 감소 효과를 나타내었으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 타이로시네이즈의 활성을 저해함을 확인하여, 상기 화학식 1 또는 2로 표시되는 화합물은 피부 미백용 화장료 조성물로 사용될 수 있음을 재확인하였다(표 2).In another embodiment of the present invention, the compound represented by the formula (1) or (2) was added to rat melanoma cells to examine the inhibitory effect on tyrosinase activity at the cell level. As a result, In particular, it was confirmed that tyrosinase activity was inhibited even at a lower concentration than that of arbutin used as a positive control, and thus the compound represented by the above formula (1) or (2) It can be used as a cosmetic composition for whitening (Table 2).
본 발명의 약학적 조성물은 피부 색소 침착을 예방하고 치료하기 위한 통상의 방법에 따라 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 에어로졸, 멸균 주사용액 등의 형태로 제형화가 가능하다.The pharmaceutical composition of the present invention may be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, aerosols, sterilized injection solutions etc. according to a conventional method for preventing and treating skin pigmentation . ≪ / RTI >
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 포함되며, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 사용될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations are prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, . In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, Can be used.
비경구투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등을 포함할 수 있다. 비수성용제와 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일 등과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the non-aqueous solvent and the suspending agent include vegetable oils such as propylene glycol, polyethylene glycol and olive oil, injectable esters such as ethyl oleate, and the like.
또한, 본 발명의 약학적 조성물은 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 담체, 부형제 또는 희석제로는 락토즈, 텍스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오즈, 메틸 셀루로오즈, 하이드록시 프로필 메틸 셀룰로오즈, 미정질 셀룰로오즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 플로필히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 이산화규소 등의 광물유 등이 사용될 수 있다.In addition, the pharmaceutical composition of the present invention may further comprise a carrier, an excipient or a diluent. Examples of the carrier, excipient or diluent include lactose, textol, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Mineral oil such as propyl methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and silicon dioxide can be used have.
본 발명에 따른 약학적 조성물의 구체적인 투여량은 제제화 방법, 환자의 상태 및 체중, 환자의 성별, 연령, 질병의 정도, 약물형태, 투여경로 및 기간, 배설 속도, 반응 감응성 등과 같은 요인들에 따라 당업자에 의해 다양하게 선택될 수 있으며, 투여량 및 횟수는 어떠한 면에서든 본 발명의 범위를 제한하는 것은 아니다.The specific dosage of the pharmaceutical composition according to the present invention depends on factors such as the formulation method, the patient's condition and body weight, the patient's sex, age, degree of disease, drug type, administration route and period, excretion rate, May be variously selected by those skilled in the art, and the dosage and the number of times do not limit the scope of the present invention in any way.
본 발명의 약학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로를 통해 투여될 수 있다. 투여의 모든 방식은 예상될 수 있으며, 예를 들어 경구, 정맥, 근육 또는 피하 주사에 의해 투여될 수 있다.The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like through various routes. All modes of administration may be expected and may be administered, for example, by oral, intravenous, intramuscular or subcutaneous injection.
본 발명의 리보플라빈 포스페이트 나트륨 또는 피탄트리올을 유효성분으로 포함하는 조성물은 멜라닌 합성을 억제하여 세포 내 멜라닌 총량을 감소시키는 효과가 있음을 확인하였으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 멜라닌 합성을 저해할 수 있으므로, 리보플라빈 포스페이트 나트륨 또는 피탄트리올을 유효성분으로 포함하는 조성물은 피부 미백용 화장료 조성물, 피부 미백용 피부 외용제 또는 건강기능식품 등으로 유용하게 사용될 수 있다.The composition comprising riboflavin phosphate or phytanetriol as an active ingredient of the present invention has the effect of inhibiting melanin synthesis and decreasing the total amount of melanin in the cells. In particular, melanin at a lower concentration than arbutin used as a positive control Therefore, a composition comprising riboflavin phosphate sodium or phytotriol as an active ingredient can be usefully used as a cosmetic composition for skin whitening, a skin external preparation for skin whitening, a health functional food, and the like.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예Example 1: 멜라닌 총량 감소 확인 1: Confirm melanin total decrease
리보플라빈 포스페이트 나트륨(sodium riboflavin phosphate) 또는 피탄트리올(phytantriol)을 마우스의 B-16 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 미백 효과를 실험하고자 하였다.The effect of sodium riboflavin phosphate or phytantriol on the cell-level whitening effect of B-16 mouse melanoma cells was investigated.
구체적으로, 배양액을 기준으로 리보플라빈 포스페이트 나트륨 또는 피탄트리올의 최종농도가 10 ㎍/㎖, 20 ㎍/㎖이 되도록 배지에 첨가하였으며, 양성 대조군인 알부틴은 100 ㎍/㎖의 농도로 배지에 첨가하였다. 음성 대조군은 배지에 추가적인 시료를 첨가하지 않았다. Specifically, the final concentration of riboflavin phosphate or phytotriol was 10 μg / ml or 20 μg / ml based on the culture medium, and arbutin, a positive control, was added to the medium at a concentration of 100 μg / ml . Negative controls did not add any additional sample to the medium.
상기 각각의 배지에서 B-16 멜라노마 세포를 3일간 배양한 후, 배양된 세포에 트립신(trypsin)을 처리하여 배양용기로부터 분리하여 원심분리하였다. 원심분리한 세포로부터 멜라닌을 추출하였으며, 구체적으로, 분리된 세포에 수산화 나트륨 용액(1N 농도) 1 ㎖를 첨가하고 10분간 가열하여 멜라닌을 녹이고, 분광 광도계를 이용하여 400 나노미터(nm)에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다. B-16 melanoma cells were cultured in the respective media for 3 days. Then, the cultured cells were treated with trypsin, separated from the culture container, and centrifuged. Melanin was extracted from the centrifuged cells. Specifically, 1 ml of a sodium hydroxide solution (1N concentration) was added to the separated cells, melanin was dissolved by heating for 10 minutes, and the absorbance at 400 nanometers And the amount of melanin produced was measured.
상기 멜라닌 양은 단위 세포수당(106 cell) 흡광도로 나타나도록 측정하였으며, 음성 대조군의 멜라닌 총량에 대한 상대적인 저해율(%)을 계산한 결과를 하기 표 1에 정리하였다.The amount of melanin was measured so as to exhibit an absorbance of 10 6 cells per unit cell, and the inhibition rate (%) relative to the total amount of melanin in the negative control group was calculated and the results are summarized in Table 1 below.
(10 ㎍/㎖)Riboflavin phosphate sodium
(10 [mu] g / ml)
(20 ㎍/㎖)Riboflavin phosphate sodium
(20 [mu] g / ml)
그 결과, 상기 표 1에서 볼 수 있듯이, 리보플라빈 포스페이트 나트륨 및 피탄트리올은 농도 의존적으로 멜라노마 세포의 멜라닌 총량을 감소시켜, 멜라닌 합성을 억제하는 효과가 있음을 확인하였으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 멜라닌 합성을 저해하여, 멜라닌 총량을 감소시키는 효능을 가짐을 확인하였다.As a result, as shown in Table 1, riboflavin phosphate sodium and pyranthr olol decreased melanoma total amount of melanoma cells in a concentration-dependent manner, confirming that melanin synthesis was inhibited, and in particular, they were used as positive control Inhibited the synthesis of melanin even at a lower concentration than that of arbutin, thereby reducing the total amount of melanin.
따라서, 리보플라빈 포스페이트 나트륨 및 피탄트리올은 멜라닌 합성을 저해하여 멜라닌 총량을 감소시켜, 피부 미백 용도로 사용될 수 있음을 알 수 있었다.Therefore, riboflavin phosphate sodium and pyrantriol inhibited melanin synthesis, thereby reducing the total amount of melanin, and thus it could be used for skin whitening purposes.
실시예Example 2: 2: 타이로시네이즈Tairosineiz (( tyrosinasetyrosinase ) 활성 감소 확인) Reduced activity check
만니톨을 마우스의 B-16 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 타이로시네이즈 활성 저해 효과를 실험하고자 하였다.Mannitol was added to the culture medium of B-16 mouse melanoma cell of mouse to test the inhibitory effect of tyrosinase activity at the cell level.
구체적으로, 배양액을 기준으로 만니톨의 최종농도가 10 ㎍/㎖, 20 ㎍/㎖이 되도록 배지에 첨가하였으며, 양성 대조군인 알부틴은 100 ㎍/㎖의 농도로 배지에 첨가하였다. 음성 대조군은 배지에 추가적인 시료를 첨가하지 않았다.Specifically, the final concentration of mannitol was added to the medium such that the final concentration of mannitol was 10 μg / ml and 20 μg / ml based on the culture, and arbutin, a positive control, was added to the medium at a concentration of 100 μg / ml. Negative controls did not add any additional sample to the medium.
상기 각각의 배지에서 B-16 멜라노마 세포를 3일간 배양한 후, 배양된 세포에 트립신(trypsin)을 처리하여 배양용기로부터 분리하여 원심분리하였다. 원심분리한 세포를 세포 용해액(1% triton-100 및 0.1% PMSF가 포함된 0.1M phosphate buffer)에 용해시켰고, 1mM의 도파(DOPA, dihydroxyphenylalanine)를 섞어 1시간 동안 37℃에서 반응시켰다. 이후 분광 광도계를 이용하여 475 나노미터(nm)에서 흡광도를 측정하여 타이로시네이즈의 활성 정도를 측정하였다. B-16 melanoma cells were cultured in the respective media for 3 days. Then, the cultured cells were treated with trypsin, separated from the culture container, and centrifuged. The centrifuged cells were dissolved in a cell lysis solution (0.1 M phosphate buffer containing 1% triton-100 and 0.1% PMSF) and reacted at 37 ° C for 1 hour with 1 mM DOPA (dihydroxyphenylalanine). Then, absorbance was measured at 475 nanometers (nm) using a spectrophotometer to measure the activity of tyrosinase.
상기 타이로시네이즈의 활성 정도는 단위 세포수당(106 cell) 흡광도로 나타나도록 측정하였으며, 음성 대조군의 타이로시네이즈의 활성에 대한 상대적인 저해율(%)을 계산한 결과를 하기 표 2에 정리하였다.The degree of activity of the tyrosinase was measured so as to show an absorbance per unit cell (10 6 cells), and the inhibition rate (%) relative to the activity of tyrosinase in the negative control group was calculated. Respectively.
(10 ㎍/㎖)Riboflavin phosphate sodium
(10 [mu] g / ml)
(20 ㎍/㎖)Riboflavin phosphate sodium
(20 [mu] g / ml)
그 결과, 상기 표 2에서 볼 수 있듯이, 리보플라빈 포스페이트 나트륨 및 피탄트리올은 농도 의존적으로 멜라노마 세포의 타이로시네이즈의 활성을 감소시키는 효과가 있음을 확인하였으며, 특히, 양성 대조군으로 사용된 알부틴보다 낮은 농도에서도 타이로시네이즈의 활성을 저해하여, 결과적으로 멜라닌 총량을 감소시키는 효능을 가짐을 확인하였다.As a result, as shown in Table 2, it was confirmed that riboflavin phosphate sodium and pyranthr olol had an effect of decreasing the activity of tyrosinase of melanoma cells in a concentration-dependent manner, and in particular, arbutin It was confirmed that the activity of tyrosinase was inhibited even at a lower concentration, resulting in the effect of reducing the total amount of melanin.
따라서, 리보플라빈 포스페이트 나트륨 및 피탄트리올은 멜라노마 세포의 멜라닌 총량을 감소시킬 뿐만 아니라, 멜라닌 합성과 관련된 효소인 타이로시네이즈의 활성을 저해함을 확인함으로써, 리보플라빈 포스페이트 나트륨 및 피탄트리올의 우수한 피부 미백 용도를 재확인하였다.Therefore, riboflavin phosphate sodium and phytotriol not only reduce the total amount of melanin in melanoma cells, but also inhibited the activity of tyrosinase, an enzyme involved in melanin synthesis. Thus, it has been found that riboflavin phosphate sodium and pyrantriol The skin whitening application was reaffirmed.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all aspects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (7)
A cosmetic composition comprising, as an active ingredient, one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytantriol, or a cosmetically acceptable salt thereof.
The cosmetic composition according to claim 1, wherein the cosmetic composition is for skin whitening.
3. The cosmetic composition according to claim 2, wherein the composition inhibits melanin synthesis inhibition, total melanin reduction, or tyrosinase activity.
4. The composition according to any one of claims 1 to 3, wherein the composition is selected from the group consisting of a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening longevity pack, a pack, a soft water, an emulsion, a makeup base, an essence, , Sunscreen creams, sun oil, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays ≪ / RTI >
A skin external preparation for improving skin whitening comprising, as an active ingredient, one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytantriol, or a pharmaceutically acceptable salt thereof.
A health functional food for improving skin whitening comprising one kind of compound selected from the group consisting of sodium riboflavin phosphate and phytantriol or a pharmaceutically acceptable salt thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170046205A KR102093781B1 (en) | 2017-04-10 | 2017-04-10 | Skin-whitening cosmetic composition containing sodium riboflavin phosphate or phytantriol as a active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170046205A KR102093781B1 (en) | 2017-04-10 | 2017-04-10 | Skin-whitening cosmetic composition containing sodium riboflavin phosphate or phytantriol as a active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180114440A true KR20180114440A (en) | 2018-10-18 |
| KR102093781B1 KR102093781B1 (en) | 2020-03-26 |
Family
ID=64133044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170046205A KR102093781B1 (en) | 2017-04-10 | 2017-04-10 | Skin-whitening cosmetic composition containing sodium riboflavin phosphate or phytantriol as a active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102093781B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100072000A (en) * | 2007-08-31 | 2010-06-29 | 디에스엠 아이피 어셋츠 비.브이. | 4-amidino benzylamines for cosmetic and/or dermatological use |
| JP2018188627A (en) * | 2017-05-05 | 2018-11-29 | ザ・スウォッチ・グループ・リサーチ・アンド・ディベロップメント・リミテッド | Epilamization agent and epilamization method using such epilamization agent |
-
2017
- 2017-04-10 KR KR1020170046205A patent/KR102093781B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100072000A (en) * | 2007-08-31 | 2010-06-29 | 디에스엠 아이피 어셋츠 비.브이. | 4-amidino benzylamines for cosmetic and/or dermatological use |
| JP2018188627A (en) * | 2017-05-05 | 2018-11-29 | ザ・スウォッチ・グループ・リサーチ・アンド・ディベロップメント・リミテッド | Epilamization agent and epilamization method using such epilamization agent |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102093781B1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102193209B1 (en) | Cosmetic composition for skin whitening comprising extract of Phragmites Communis | |
| JP4233734B2 (en) | Skin external preparation for whitening | |
| KR20130017159A (en) | Composition for skin lightening comprising extract of ecklonia cava treated by enzyme | |
| KR102002627B1 (en) | A skin-whitening composition comprising spinosin | |
| KR101299024B1 (en) | Cosmetics composition for skin lightening color, antioxidantsand and method for preparing the same | |
| KR102283040B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising atractylenolide I | |
| WO2018053706A1 (en) | Composition comprising paeoniflorin or albiflorin analogue, method of preparation thereof | |
| KR102356451B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising Shanzhiside methylester or a pharmaceutically acceptable salt thereof | |
| KR102348149B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising parthenolide | |
| KR102039608B1 (en) | Composition including midodrine and its uses | |
| KR102178889B1 (en) | Skin-whitening cosmetic composition containing Mannitol as a active ingredient | |
| KR102002628B1 (en) | A skin-whitening composition comprising swertiajaponin | |
| KR20180114440A (en) | Skin-whitening cosmetic composition containing sodium riboflavin phosphate or phytantriol as a active ingredient | |
| KR102324182B1 (en) | Skin-whitening cosmetic composition containing Orotic acid as a active ingredient | |
| KR102324181B1 (en) | Skin-whitening cosmetic composition containing Mevalonolactone as a active ingredient | |
| KR102293928B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising Wogonoside or a pharmaceutically acceptable salt thereof | |
| KR102265413B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising prim-O-glucosylcimifugin or a pharmaceutically acceptable salt thereof | |
| KR20180042707A (en) | Composition for skin improvement containing strychnine | |
| KR102225547B1 (en) | Cosmetic composition comprising substance P for whitening skin | |
| KR102022620B1 (en) | Composition for improving skin wrinkle comprising spinosin | |
| KR20160119548A (en) | Skin whitening composition comprising Scrophularia buergeriana hot water extract as an active ingredient | |
| KR20220055154A (en) | Composition comprising vicenin-2 | |
| KR102272477B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising 4'-O-β-D-glucosyl-5-O-methylvisamminol or a pharmaceutically acceptable salt thereof | |
| KR102277526B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising acanthopanax senticosides B or a pharmaceutically acceptable salt thereof | |
| KR102228039B1 (en) | Cosmetic or pharmaceutical composition for skin whitening comprising Astragaloside I or a pharmaceutically acceptable salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |